Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $30.93 in the prior trading day, Twist Bioscience Corp (NASDAQ: TWST) closed at $30.39, down -1.75%. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 1.13 million shares were traded.
Ratios:
Our goal is to gain a better understanding of TWST by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.51. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 08 ’25 when Finn Patrick John sold 20,000 shares for $32.31 per share. The transaction valued at 646,260 led to the insider holds 242,660 shares of the business.
Cho Dennis sold 5,000 shares of TWST for $163,590 on May 07 ’25. The insider now owns 105,849 shares after completing the transaction at $32.72 per share. On May 08 ’25, another insider, Finn Patrick John, who serves as the Officer of the company, bought 20,000 shares for $32.31 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.24 while its Price-to-Book (P/B) ratio in mrq is 4.13.
Stock Price History:
Over the past 52 weeks, TWST has reached a high of $60.90, while it has fallen to a 52-week low of $28.46. The 50-Day Moving Average of the stock is -19.38%, while the 200-Day Moving Average is calculated to be -30.02%.
Shares Statistics:
A total of 59.86M shares are outstanding, with a floating share count of 56.67M. Insiders hold about 5.42% of the company’s shares, while institutions hold 107.41% stake in the company.
Earnings Estimates
The company has 4.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.43 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$2.14 and -$2.32 for the fiscal current year, implying an average EPS of -$2.24. EPS for the following year is -$1.74, with 5.0 analysts recommending between -$1.34 and -$2.45.
Revenue Estimates
10 analysts predict $95.52M in revenue for the current quarter. It ranges from a high estimate of $96.39M to a low estimate of $94M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $81.46MFor the next quarter, 10 analysts are estimating revenue of $99.22M. There is a high estimate of $100.1M for the next quarter, whereas the lowest estimate is $97.34M.
A total of 11 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $377.67M, while the lowest revenue estimate was $372.75M, resulting in an average revenue estimate of $376M. In the same quarter a year ago, actual revenue was $312.97MBased on 11 analysts’ estimates, the company’s revenue will be $442.09M in the next fiscal year. The high estimate is $448M and the low estimate is $427M.
